Ensysce Biosciences (ENSC) Projected to Post Earnings on Friday

Ensysce Biosciences (NASDAQ:ENSC) will likely be releasing its Q3 2026 results on Friday, November 13th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $1.20 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Ensysce Biosciences (NASDAQ:ENSC) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.20) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.20). Ensysce Biosciences had a negative net margin of 280.53% and a negative return on equity of 2,550.30%. The business had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.20 million. On average, analysts expect Ensysce Biosciences to post ($0.60) EPS for the current fiscal year and ($0.06) EPS for the next fiscal year.

Ensysce Biosciences Stock Up 0.0%

Shares of Ensysce Biosciences stock opened at $0.36 on Thursday. The firm’s 50 day moving average price is $0.45 and its 200-day moving average price is $0.42. Ensysce Biosciences has a 52-week low of $0.23 and a 52-week high of $2.17. The company has a market cap of $7.01 million, a P/E ratio of -0.13 and a beta of 1.11.

Wall Street Analyst Weigh In

ENSC has been the subject of several recent analyst reports. Cantor Fitzgerald assumed coverage on shares of Ensysce Biosciences in a research note on Tuesday, October 20th. They issued an “overweight” rating and a $2.00 target price for the company. Weiss Ratings raised shares of Ensysce Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Finally, Wall Street Zen raised Ensysce Biosciences to a “hold” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $2.00.

About Ensysce Biosciences

Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing prescription medicines designed to address opioid abuse, misuse and overdose. The company’s technology is intended to preserve the therapeutic benefits of opioid pain medicines while incorporating mechanisms that may reduce the risks associated with tampering or excessive dosing. Ensysce’s lead product candidate, PF614, is an investigational extended-release oxycodone prodrug designed to be activated in the gastrointestinal tract.